ARTICLE | Company News

Biocept, J&J sales and marketing update

February 24, 2014 8:00 AM UTC

Medicare contractor Palmetto GBA LLC may not reimburse circulating tumor cell (CTC) assays for malignant diagnoses, including the CellSearch Circulating Tumor Cell Kit from Johnson & Johnson's Veridex LLC unit and the OncoCEE-BR breast cancer test from Biocept. Palmetto - which covers West Virginia, Virginia, North Carolina and South Carolina - has previously provided limited coverage for CellSearch, but noted in a draft non-coverage determination that there has been no data showing CTC assays improve patient outcomes or change physician management. Comments are due Feb. 24. J&J said a final decision is expected in early March. ...